Vimarsana
Biggest News Aggregation in the World

Hyperactivity Using Solriamfetol News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Hyperactivity Using Solriamfetol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Hyperactivity Using Solriamfetol Today - Breaking & Trending Today

Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of ... - Vimarsana News

Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of ...

Published: July 7, 2023

NEW YORK, July 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders,

Source: eagletribune.com
Related Topics:
United StatesNew YorkMark JacobsonDarren OplandAmerican Psychiatric AssociationA Foundation For Clinical NeuroscienceDrug AdministrationAxsome Therapeutics IncCorporate CommunicationsWorld Trade CenterNational Comorbidity Survey ReplicationForward TreatmentAttention DeficitHyperactivity Using SolriamfetolSymptom Report ScaleAttention Deficit Hyperactivity DisorderAxsome TherapeuticsPsychiatric AssociationStatistical ManualMental DisordersAmerican Psychiatric PublishingPsychiatry ReportsMolecular NeuropharmacologyClinical NeuroscienceSecond Edition
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults - Vimarsana News

Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults

Published: July 7, 2023

NEW YORK, July 07, 2023 -- Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today announced...

Source: marketscreener.com
Related Topics:
New YorkUnited StatesMark JacobsonDarren OplandWorld Trade CenterA Foundation For Clinical NeuroscienceAxsome Therapeutics IncCorporate CommunicationsNational Comorbidity Survey ReplicationAmerican Psychiatric AssociationDrug AdministrationForward TreatmentAttention DeficitHyperactivity Using SolriamfetolSymptom Report ScaleAttention Deficit Hyperactivity DisorderAxsome TherapeuticsPsychiatric AssociationStatistical ManualMental DisordersAmerican Psychiatric PublishingPsychiatry ReportsMolecular NeuropharmacologyClinical NeuroscienceSecond Edition